The company said that organic revenue growth for the quarter ended September 30, 2024 reflected increases in CAG Diagnostics recurring revenue, veterinary software, services and diagnostic imaging revenue, and Water revenue, while LPD revenue decreased. It said the shipping-day benefit increased revenue growth by approximately 1%, acquisitions added 0.4%, and changes in foreign currency exchange rates added 0.1%.

1. 01

   The company said that organic revenue growth for the quarter ended September 30, 2024 reflected increases in CAG Diagnostics recurring revenue, veterinary software, services and diagnostic imaging revenue, and Water revenue, while LPD revenue decreased. It said the shipping-day benefit increased revenue growth by approximately 1%, acquisitions added 0.4%, and changes in foreign currency exchange rates added 0.1%.

2. 02

   IDEXX said its total company gross profit margin rose 120 basis points for Q3 2024, and that changes in foreign currency exchange rates lowered it by approximately 20 basis points. By segment, the company said the CAG gross profit margin rose 140 basis points, the Water margin fell 50 basis points, and the LPD margin fell 270 basis points.

3. 03

   The company said cash provided by operating activities for the 9 months ended September 30, 2024 increased $10.3 million from the same period a year earlier. It said cash used in investing activities was $167.2 million and cash used in financing activities was $645.3 million over the same period, and that share repurchases totaled $591.0 million.

4. 04

   The company said that as of September 30, 2024, cash and cash equivalents were $308.6 million (compared with $453.9 million as of December 31, 2023), and working capital was $424.5 million. It said $1.25 billion in borrowings was outstanding under its Credit Facility, and remaining borrowing availability was $998.2 million, with $250.0 million of outstanding borrowings.

Key figures

Quarter ended September 30, 2024

Revenue

$976M

Operating income

$304M

Net income

$233M

EPS

$2.80

Gross profit

$596M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.